Topic: Opioid Epidemic

Interventions of Interest: Hysingla® ER (Hydrocodone, Purdue) Vantrela® (Hydrocodone , Teva) Arymo® ER ( Morphine, Egalet) Embeda® (Morphine + naltrexone, Pfizer) Morphabond® (Morphine extended release, Inspirion Delivery Technologies) OxyContin® TR (Oxycodone, Purdue) Xtampza®ER (Oxycodone, Collegium Pharmaceutical Inc) Targiniq® (Oxycodone + naloxone extended release, Purdue) Troxyca® ER (Oxycodone + naltrexone, Pfizer) RoxyBond® (Oxycodone, Inspirion Delivery Technologies) […]

Interventions of Interest: Buprenorphine (Subutex®, Reckitt Benckiser Pharmaceuticals Inc. Buprenorphine and naloxone (Suboxone®, Indivior Inc.) Dose-tapering strategies for methadone or Suboxone, with or without naltrexone (Revia®, Duramed Pharmaceuticals, Inc. Naltrexone (Vivitrol®, Alkermes, Inc.) Use of naltrexone alone without prior stabilization on methadone or buprenorphine Drug-free opioid withdrawal management A 2014 review assessed MAT with methadone […]

Interventions of interest: Monthly buprenorphine injection (Sublocade™, Indivior) Buprenorphine implant (Probuphine®, Braeburn/Titan) Buprenorphine extended release injection (Sublocade®, Braeburn) These therapies were compared to MAT with methadone, buprenorphine/naloxone sublingual film (Suboxone®, Indivior), and injectable naltrexone (Vivitrol®, Alkermes). Opioid use disorder has reached a critical level in the United States, driven by over-prescription and diversion of opioid […]

ICER assessed the comparative clinical effectiveness and economic value of supervised injection facilities (SIFs). ICER has reviewed other related topics, such as abuse-deterrent opioid formulations, medication-assisted treatment for opioid use disorder, and non-drug interventions for lower back pain. This review reinforced ICER’s commitment to provide an independent evaluation of the evidence around interventions that target […]

ICER assessed the comparative clinical effectiveness and economic value of digital health technologies (DHTs) for opioid use disorder. ICER has reviewed other related topics, such as abuse-deterrent opioid formulations, medication-assisted treatment for opioid use disorder, and non-drug interventions for lower back pain. The Midwest CEPAC determined current evidence is inadequate to demonstrate a net health […]